White Paper
Ensuring Success with Capital and Time Efficiency
This EVERSANA white paper examines the challenges first-time biopharma companies face when commercializing new products and presents an integrated commercialization model designed to improve launch success. It highlights four major barriers: lower launch effectiveness, high capital requirements, lengthy preparation timelines, and regulatory risk. By leveraging pre-built infrastructure, experienced teams, and a single-partner commercialization approach, EVERSANA claims companies can reduce launch costs by about 25%, shorten preparation time by up to 50%, and improve operational flexibility. Case studies demonstrate faster launches, reduced investment, improved forecast performance, and lower financial risk, enabling emerging biopharma companies to achieve more efficient and successful produ
